Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Mitchell

Showing results (11-20 of 249) with videos related to

Pageof 25
Sort By:
Nature Biotechnology|October 11, 2008
Plasma product companies outmuscle small recombinant playersPeter Mitchell
Nature Biotechnology|August 9, 2008
Pharma to boycott UK?Peter Mitchell
Nature Biotechnology|January 12, 2011
Biogen Idec restructures, sharpens neurology focusPeter Mitchell
Nature Biotechnology|April 17, 2004
The changing attitude of European VCsPeter Mitchell
Nature Biotechnology|May 10, 2008
No way out for small public firms?Peter Mitchell
Nature Biotechnology|March 5, 2002
A perspective on protein microarraysPeter Mitchell
Lancet (London, England)|May 10, 1997
Drug industry lobbies against European research-data directivePeter Mitchell
Nature Biotechnology|September 3, 2002
EMEA approves OGS drug rejected by FDAPeter Mitchell
Nature Biotechnology|October 2, 2002
Companies struggle amid stock market gloomPeter Mitchell
Nature Biotechnology|August 2, 2003
Public markets show signs of lifePeter Mitchell
Pageof 25

Showing results (11-20 of 249) with videos related to

Sort By:
Pageof 25
Nature Biotechnology|October 11, 2008
Plasma product companies outmuscle small recombinant playersPeter Mitchell
Nature Biotechnology|August 9, 2008
Pharma to boycott UK?Peter Mitchell
Nature Biotechnology|January 12, 2011
Biogen Idec restructures, sharpens neurology focusPeter Mitchell
Nature Biotechnology|April 17, 2004
The changing attitude of European VCsPeter Mitchell
Nature Biotechnology|May 10, 2008
No way out for small public firms?Peter Mitchell
Nature Biotechnology|March 5, 2002
A perspective on protein microarraysPeter Mitchell
Lancet (London, England)|May 10, 1997
Drug industry lobbies against European research-data directivePeter Mitchell
Nature Biotechnology|September 3, 2002
EMEA approves OGS drug rejected by FDAPeter Mitchell
Nature Biotechnology|October 2, 2002
Companies struggle amid stock market gloomPeter Mitchell
Nature Biotechnology|August 2, 2003
Public markets show signs of lifePeter Mitchell
Pageof 25